#2 - Pfizer (NYSE:PFE)
There’s been some speculation about why Pfizer (NYSE: PFE) stock is not soaring. The company along with BioNTech (NASDAQ: BNTX) was the first to receive Emergency Use Authorization (EUA) for its Covid-19 vaccine, Comirnaty. And it was also the first to receive FDA approval as well. This is the best evidence of Pfizer’s purposeful shift into the biopharma space paying off.
However, there’s much more to like about Pfizer than the revenue that Comirnaty will deliver for the company in 2022 and perhaps beyond. To begin with, Pfizer is said to be in the process of developing its own Covid-19 pill to compete with Merck. However, it goes far beyond that. The company has several oncology drugs, headlined by Ibrance, and an anticoagulant, Eliquis, that are showing year-over-year revenue growth. And the company has one of the most robust pipelines in the industry. Of the company’s 100 “discovery projects,” 23 are in late-stage (Phase 3) studies.
With any pharmaceutical stocks, investors should be looking for multiple revenue streams. And in that context, Pfizer is delivering in ways that set it apart from other stocks in the sector.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $26.36
- Consensus Rating
- Hold
- Ratings Breakdown
- 7 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.14 (21.9% Upside)
